SAN DIEGO--(BUSINESS WIRE)--Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Vijay Mahant, PhD, to its Scientific Advisory Board. In this role, Dr. Mahant will be leveraging his pharmacogenomics and diagnostics experience to lead the company in identifying biomarkers that have the potential to determine which patients will positively respond to the ValloVax immune therapy.
“Precision or personalized medicine that tailors therapeutic intervention to the individual needs of the patient can significantly optimize clinical response. Our goal is to eventually develop a simple and efficient companion test that would identify which patients will respond to ValloVax with minimal side effects. In this manner, we can ensure that we treat only a subset of patients who will have the best response; thereby reducing the burden on the payer/patient and increasing our likelihood for market approval,” stated Samuel C. Wagner, President and CEO of Batu Biologics.
Dr. Mahant is a scientist and an entrepreneur with 30 years of experience in immune and molecular diagnostics. Dr. Mahant graduated from Loughborough University of Technology (UK) and he received his second post-doctorate from UT Health Science Center at Houston/MD Anderson, TX, USA. Subsequent to his academic experience, he has founded and held executive positions in several companies with diverse experience in research and development. He successfully licensed his technology to Qualigen for point-of care diagnostics that have been FDA cleared and used in physicians’ offices internationally. Following his role as the CSO with Qualigen, Dr. Mahant played an instrumental role as the executive VP, R&D at Autogenomics, a molecular diagnostic company in California, specializing in pharmacogenomics.
"Genetic differences in drug metabolism in individuals can affect an individual's response to drugs, both in therapeutic effect and in adverse effects. Gene-guided drug therapy is thus like the ‘navigational or GPS system’ for integration in drug discovery, clinical trials, and for the identification of the best possible drug therapy of an individual. I am extremely excited about collaborating with Batu Biologics to fully optimize the potential of their therapeutics," commented Dr. Mahant.
Batu Biologics has filed an Investigational New Drug (IND) application with the FDA and is awaiting approval to initiate a Phase I study for ValloVax™ in patients with non-small cell lung cancer.
About Batu Biologics
Batu Biologics is an immuno-oncology company developing novel gene and cellular based therapies for the treatment of cancer. The Company has filed an IND application for its lead therapeutic, ValloVax™, a multivalent therapeutic vaccine for Non Small Cell Lung Cancer targeting several tumor-angiogenesis associated antigens. ValloVax™ has demonstrated strong inhibition of tumor growth in several histologically distinct tumor models, and the company is currently raising funds that will enable the completion of a Phase I clinical study. The company maintains research facilities at JLABS, located in the Torrey Pines-area biotech cluster of San Diego.